8-K: Centessa Pharma Secures $250M ATM Equity Offering

Centessa Pharmaceuticals plc has entered into an amended sales agreement with Leerink Partners LLC to potentially sell up to $250 million in American Depositary Shares through an at-the-market offering.

Summary

• Centessa Pharmaceuticals plc (the Company) entered into an Amended and Restated Sales Agreement with Leerink Partners LLC on November 24, 2025.
• The agreement allows the Company to issue and sell up to $250 million of its American Depositary Shares (ADSs) through Leerink Partners LLC as its sales agent.
• Sales will be conducted in one or more "at the market" offerings, as defined in Rule 415(a)(4) of the Securities Act.
• Leerink Partners LLC will receive a commission of up to 3.0% of the gross proceeds from each sale.
• The Company will reimburse Leerink Partners LLC for the reasonable fees and expenses of their legal counsel incurred in connection with entering into the agreement, up to $150,000.
• The Company is not obligated to make any sales, and there is no assurance regarding the price, amount, or timing of any sales.
• Net proceeds are expected to be used for working capital, capital expenditures, and general corporate purposes.
• This agreement amends and restates a previous sales agreement dated January 27, 2023.

Sentiment

Score: 7

Explanation: The announcement indicates a proactive step to secure significant capital, providing financial flexibility for future operations and strategic initiatives. While it introduces potential dilution, the ability to raise funds opportunistically is a positive for a growth-oriented company in the pharmaceutical sector.

Positives

• Provides Centessa Pharmaceuticals with access to up to $250 million in capital through an "at the market" equity offering.
• The "at the market" structure offers flexibility in raising capital over time, allowing the company to tap into the market opportunistically.
• Proceeds are earmarked for general corporate purposes, including working capital and capital expenditures, which supports ongoing operations and potential growth initiatives.

Negatives

• The offering could lead to significant dilution for existing shareholders if the full $250 million is sold, especially if sales occur at lower share prices.
• There is no assurance that the Company will sell any Placement Shares or as to the price or amount of shares sold, introducing uncertainty regarding future capital availability.
• The Company will incur commissions of up to 3.0% of gross proceeds and up to $150,000 in legal fees for the agent, which will reduce net proceeds.

Risks

• Dilution Risk: The issuance and sale of up to $250 million in ADSs could dilute the ownership interest of existing shareholders.
• Market Price Volatility: The price and amount of ADSs sold are not determinable, and sales could occur at unfavorable market prices.
• No Obligation to Sell: The Company is not obligated to sell any Placement Shares, meaning the anticipated capital may not be fully realized.
• Market Conditions: The Agent's ability to sell Placement Shares is subject to commercially reasonable efforts consistent with normal trading and sales practices, implying market conditions could impact sales.
• Regulatory Risks: The Company must comply with various SEC and Nasdaq rules, and any non-compliance could halt the offering.
• Material Adverse Change: The Agent has the right to terminate the agreement if a Material Adverse Change occurs, which could cut off access to capital.
• Suspension of Trading: Suspension or limitation of trading in ADSs on Nasdaq could impair the Agent's ability to sell shares.
• General Market Conditions: Outbreaks of hostilities, crises, or substantial changes in financial or economic conditions could impair the Agent's ability to sell shares.

Future Outlook

The Company expects to use any net proceeds from the offering for working capital, capital expenditures, and general corporate purposes. No assurance can be given regarding the actual amount or price of shares sold, or the dates of such sales.

Management Comments

• The Company expects to use any net proceeds for working capital, capital expenditures and for general corporate purposes.

Industry Context

At-the-market (ATM) offerings are a common financing tool for publicly traded companies, particularly in the biotechnology and pharmaceutical sectors, to raise capital flexibly and opportunistically without the need for a traditional underwritten offering. This allows companies to access capital as needed, often to fund ongoing research and development, clinical trials, or general operational expenses, aligning with typical capital-intensive industry trends.

Comparison to Industry Standards

• The commission rate of up to 3.0% for an ATM offering is within the typical range for such agreements in the biotechnology and pharmaceutical industries, which often see rates between 1.5% and 3.5%.
• The maximum offering size of $250 million is substantial and provides significant financial flexibility, comparable to capital raises undertaken by other mid-to-large cap biotech firms for pipeline development or general corporate needs.
• The use of proceeds for working capital, capital expenditures, and general corporate purposes is standard practice for companies in this sector, reflecting the continuous need for funding for R&D and operational scale-up.

Stakeholder Impact

• Shareholders: Potential for dilution due to the issuance of new ADSs. Increased financial flexibility for the company could support long-term value creation.
• Employees: Enhanced financial stability may support ongoing operations and job security.
• Customers/Suppliers: Improved financial position could ensure continued operations and ability to meet obligations.
• Creditors: A stronger balance sheet from capital infusion could reduce credit risk.

Next Steps

• The Company may, from time to time, issue and sell Placement Shares through Leerink Partners LLC.
• Leerink Partners LLC will use commercially reasonable efforts to sell Placement Shares based on instructions from the Company.
• The Company will file prospectus supplements detailing the number of Placement Shares sold, net proceeds, and compensation.
• The Company will continue to comply with SEC reporting requirements and Nasdaq listing standards.

Key Dates

Recommendation

The ATM offering provides Centessa Pharmaceuticals with crucial financial flexibility, which is a positive for a company in the capital-intensive pharmaceutical sector. However, the potential for significant dilution, especially given the "at the market" nature where sales price is not fixed, introduces uncertainty. Without specific positive operational updates or pipeline advancements, this financing event primarily addresses liquidity and operational runway, warranting a "hold" as investors await further clarity on how this capital will translate into tangible progress and value creation. The market's reaction to dilution risk versus financial stability will be key.

Keywords

Centessa Pharmaceuticals, CNTA, At-the-Market Offering, ATM, Equity Offering, ADS, American Depositary Shares, Capital Raise, Leerink Partners, SEC Filing, Form 8-K, Dilution, Biotechnology, Pharmaceuticals